My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

60.18 +2.51 (+4.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
From Guardant Health, Inc.
Via Business Wire
Key Takeaways From Guardant Health Analyst Ratings
 
Via Benzinga
Assessing Guardant Health: Insights From 7 Financial Analysts
 
Via Benzinga
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Why Guardant Health Stock Just Crashed 10%
Guardant Health needs cash. Until it can get it from selling enough services, it must sell its own shares instead. 
Via The Motley Fool
PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
Via AB Newswire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor is making moves this summer. 
Via The Motley Fool
Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor was a buyer at the end of a very volatile trading week. 
Via The Motley Fool
Cathie Wood's Ark Invest Continues Loads Up On $6.05M Worth Of Robinhood Shares Amid Bitcoin Rebound, Dumps Zoom Stock
On Thursday, Cathie Wood-led Ark Invest made some significant trades, notably buying Robinhood Markets Inc (NASDAQ:HOOD) and selling Zoom Video Communications Inc (NASDAQ:ZM). 
Via Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q2 2024
GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
The company expects stronger second-half sales vs. the first half of 2024. 
Via Investor's Business Daily
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions. 
Via The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare... 
Via Benzinga
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
From Guardant Health, Inc.
Via Business Wire
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
The investment banking firm says these companies are among the best stocks to buy and have some strong tailwinds behind them. 
Via InvestorPlace
3 Precision Medicine Stocks Tailoring Treatments
With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider. 
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
 
Via Benzinga
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.